A sensitive, nonisotopic hybridization assay termed "dual capture" is described. The assay rapidly and specifically detects very low levels of target nucleic acids and organisms. The assay is based on the principles of sandwich hybridization, reversible target capture, and Q-Beta replicase amplification. The assay can be completed in less than 4 h, and in the described model format, it detects Chlamydia trachomatis rRNA or rDNA.
A large variety of nucleic acid probe-based hybridization assays for the detection of infectious agents have been described (17) . However, a number of practical considerations have delayed their widespread introduction in clinical testing laboratories. In particular, it is well recognized that very high sensitivity is required for the detection of clinically important pathogens directly from specimens. This prompted the intensive development of amplified nucleic acid assays including PCR, ligase chain reaction, transcription amplification system, self-sustained sequence replication, nucleic acid sequencebased amplification, strand displacement amplification, repair chain reaction (15) , branched DNA signal amplification, and Q-Beta replicase probe amplification.
Here we describe a novel nonisotopic amplified nucleic acid assay for the detection of Chlamydia trachomatis that uses sandwich hybridization, reversible target capture, and Q-Beta replicase amplification. The concept of sandwich hybridization was introduced by Ranki et al. (13) . The basic method involves the hybridization of two probes to the target nucleic acid, at least one of which must hybridize specifically. A number of variations on this basic theme have been developed, but in general, such single-capture methods are limited to a sensitivity of about 106 molecules by the nonspecific binding of the unhybridized reporter probe to the solid support. Recognizing not only that nonspecific binding is a function of the chemical nature of the solid support but also that it is driven by the concentration of labeled probe, Morrissey et al. (9) developed a method of noise reduction termed reversible target capture (RTC). RTC involves the iterative capture and elution (cycling) of probe-target hybridization complexes on solid supports. It is capable of reducing the amount of unhybridized reporter probe between 103-and 104-fold during each cycle.
We report on the basic assay methodology and its performance in the detection of C. trachomatis. Q-Beta replicase is an RNA-dependent RNA polymerase derived from the bacteriophage Q-Beta (4). The enzyme is capable of replicating a limited family of RNA molecules, a number of which have been engineered to contain probe sequences (2, 5, 6) . Q-Beta replicase copies the template RNA, producing a complementary product strand in as little as 12 s (4, 8, 10) . Since the daughter strands are also templates for the enzyme, RNA production proceeds exponentially. A single probe molecule can yield an easily detectable amount of product RNA in a 15-min amplification reaction. Thus, in principle, an extremely small number of target molecules can be detected in such an assay.
This report describes an assay format, termed "dual capture," which is a nonisotopic version of the RTC assay in which the isotopically labeled probes have been replaced with novel RNA probes that are replicatable by Q-Beta replicase (5, 6 ).
The assay is highly sensitive and specific and can detect the presence of C. trachomatis nucleic acid in patient samples.
MATERIALS AND METHODS
Paramagnetic particles. Oligo(dT)-derivatized ferromagnetic particles (Advanced Magnetics, Inc., Cambridge, Mass.) were prepared as described previously (9 (14) .
Preparation of patient specimens. Coded samples were submitted to our laboratory from the University of Massachusetts Medical Center as described previously (la). For culture, a 0.3-ml aliquot of sample in 2-SP was cultured in shell vials, and the shell vials were incubated for 3 days and stained with a fluorescein-conjugated monoclonal antibody as described previously (la). For the dual-capture assay, a 0.5-ml portion of the sample was pelleted by centrifugation in a microcentrifuge at 13,000 x g for 10 min. The supernatant was removed and the pellet was suspended in 0.21 ml of 1% Nonidet P-40. A 0.1-ml aliquot was mixed with 0. GATGCCCAAATACGCCACAT-(dA)150, respectively. Both of these probes were modified at the 5' ends to contain a primary amine by the addition of an aminopropyl-modified cytosine phosphoramidite. Deprotection of the phosphates and nucleotide bases was accomplished by standard methods, and the crude oligonucleotide mixtures were purified by reversephase high-pressure liquid chromatography. The amino-modified oligonucleotide was labeled with biotin by using FluoReporter biotin labeling kit F-2610 (Molecular Probes, Eugene, Oreg.). A tail of about 150 deoxyadenosine residues was added to the 3' end of the capture probe by using terminal deoxynucleotidyl transferase (9) .
A Q-Beta replicatable RNA reporter probe containing a probe sequence complementary to the Chlamydia target was transcribed from a recombinant plasmid with T7 RNA polymerase (2) . This RNA transcript is referred to as C29 and is used in the examples described below as an MDV reporter probe. MDV is an abbreviation for midivariant RNA, which is the most extensively studied nonviral substrate for Q-Beta replicase into which probe sequences have been cloned (6 ion-exchange filters (Whatman). The transcripts were checked for size and integrity by denaturing polyacrylamide gel electrophoresis. The RNA substrates were diluted and tested in duplicate for replication efficiency (2) . Dual-capture RTC format. A schematic representation of the dual-capture RTC format is given in Fig. 1 , and details of the assay are provided below. The hybridization and reversible target capture reactions were carried out with a tube rack, magnetic separator block, and aspirator head specially designed to hold 96 1-ml tubes (Micronic B.V., Lelystad, The Netherlands), as shown in Fig. 2 . Hybridization and reversible target capture reactions were conducted at 37°C by keeping the magnetic separator and tubes partially submerged in a circulating water bath. In all, four sets of racked tubes were required for all steps of the assay up to the amplification step. The reaction mixtures were assembled in the first set of tubes, and at every cycle of the assay the reaction mixture was transferred to another rack of clean tubes. This configuration was compatible with a microtiter plate format, enabling us to perform manipulations with multichannel pipettors.
The samples containing various amounts of purified 16S
rRNA, 16S rDNA, elementary bodies, or human specimans were diluted in sample processing buffer to a final concentra- The set consists of three components: a test tube rack that holds 96 1-ml tubes with the same configuration and spacing as those of microtiter plates, a magnetic separator block which holds the tube rack, and an eight-channel aspirator head which is hooked up to a collection flask on standard laboratory vacuum lines. Alternately, the liquid can be removed and transferred to another rack of tubes by using any number of standard multichannel microtiter pipettors. (B) The rack fits into the magnetic separator block in which magnetic beads are rapidly pulled to the sides of the tube, allowing removal of liquid by the eight-channel aspirator head.
capture probe-C29 RNA mixture to yield a final concentration of 100 ng/ml for both capture and detector probes.
Following the 30-min hybridization at 37°C, 100 ,u of a suspension of 0.04% streptavidin-derivatized paramagnetic particles in bead blocking buffer was added to each of the tubes. After mixing, the tubes were incubated at 37°C for 5 min to capture the ternary hybrids (capture probe-target-detector probe). The particles containing the captured hybrids were collected onto the sides of the tubes by using a specially designed magnetic separator for 2 min, and the supernatants were removed by aspiration. C29 detector probe that had not bound to the target was removed by washing the magnetic particles twice with 200 RI of low-salt buffer (100 mM Tris [pH 8 .1], 20 mM EDTA, 25 mM NaCl, 0.2% Sarkosyl, 0.05% BSA, and 0.05% Bronopol). Washing was accomplished by vortexing the tubes for 30 s and separating the particles from the buffer as described above.
The target-detector probe hybrid was released from the initial solid support by adding 100 ,ul of GuSCN release buffer (240 mM Tris-HCl [pH 7.8], 60 mM EDTA, 3 M GuSCN, 0.6% Sarkosyl) to all tubes, mixing, and incubating the tubes for 5 min at 37°C. The biotinylated capture probe dissociates from the target and remains bound to the streptavidin particles under these conditions. After the 5-min incubation the particles were collected onto the sides of the tubes by using the magnetic separator, and the supernatants containing the released reporter probe-target hybrids were transferred to a clean set of tubes. To all of the tubes, 50 p.1 of 300 ng of dA-tailed capture probe 781 per ml of probe dilution buffer was added to yield a final concentration of 100 ng/ml. The tubes were vortexed for 30 s and then incubated for 30 min at 37°C to allow the second (dA-tailed) capture probe 781 to hybridize to the targetdetector probe complex. To all of the tubes, 250 p.1 of 0.05% dT14 particles in the bead blocking buffer was added. The ternary complexes were captured onto the dT beads by incubating them for 5 min at 37°C. Particles were washed three times with 200 p.l of high-salt wash buffer (100 mM Tris [pH 8.1], 20 mM EDTA, 300 mM NaCl, 0.5% Sarkosyl, 0.5% BSA, 0.5% Bronopol) and ternary complexes were released by using 100 p.l of low-salt buffer per tube. The low-salt buffer disrupts the dA-dT hybrids made between the dA tail of the second capture probe and the oligo(dT) on the solid support, thereby releasing the intact capture probe-target-detector probe ternary hybrid complex into the solution.
Each of the released supernatants was transferred to a clean set of tubes as described above, and 100 p. Fig. 3 . A 510-nm-wavelength light from a xenon flash lamp is transmitted to the reaction via a fiber optic line. Fluorescence is received through another fiber optic line into a 615-nm emission filter. The sensor, containing both fiber optic lines, is fixed to a tram on an XY table, which enables it to read all 96 positions through the bottom of the heater block. Fluorescence was measured in each reaction tube every 40 s during a 30-min time period. The signal is received by a photomultiplier tube, which relays it to an analog-todigital converter.
The information was received, analyzed with a proprietary software package, and plotted by an International Business Machines 386 computer. A depiction of the plotted data is shown in Fig. 4 . Figure 4 represents an amplification of diluted C29 detector probe in the amplification release buffer. A 50-,ul aliquot containing 10-fold dilutions of C29 molecules was added to an equal volume of the Q-Beta replicase buffer. The software calculates a parameter termed "response time" (3) . This was defined as the time required to reach an arbitrary (fixed) level of RNA in each reaction tube. In the present case, the response time corresponds approximately to the time at which the fluorescence signal rises just above the baseline fluorescence because of the free propidium iodide in the reaction mixture. The response time is inversely proportional to the logarithm of the number of detector molecules present at the start of the amplification reaction. igher target concentrations, the response times of Assay specificity. The specificity of the C. trachomatis assay nples were faster than those of the zero-target was examined by testing samples containing 1011 C. psittaci 16S ch responded. In addition, the mean response rRNA molecules in the absence and presence of various levels of C. trachomatis rRNA. The results of the study (Table 1) show both the qualitative data, i.e., the number of reactions in which amplification was Detection of C. trachomatis in patient samples. Ninety-four urogenital samples containing six culture-positive samples were tested in duplicate. Five of these culture-positive samples were positive by Q-Beta amplification. For culture 300 ,ul of sample was inoculated onto the cells, while 50 ,ul of sample was used in duplicate for the dual-capture assay. Of the 88 culturenegative samples, the assay was concordant with 85 samples. However, three culture-negative samples were positive by our assay (Table 2 ).
DISCUSSION
The dual-capture assay format incorporates the background reduction principles of reversible target capture (9) . However, there is one significant conceptual modification in this chemistry which permits the background to be driven down even further. The term dual capture incorporates an additional hybridization and capture step early in RTC that uses a ligand-antiligand capture pair distinct from that which is used later in the assay to cycle target-probe complexes on and off magnetic particles.
The following are two key design elements of the dual- a A 300-,ul aliquot of the specimen was inoculated onto HeLa 229 cells seeded on coverslips for culture and stained after 3 days. The equivalent of 50 ,ul of specimen was tested in duplicate by the dual-capture assay. Specimens which gave signals in both replicates were considered positive. capture chemistry. (i) The hybrid between the first capture probe and the target sequence is weaker than the hybrid between the reporter probe and its target sequence, and (ii) there is a lack of cross-affinity of the first capture probe ligand to the second antiligand solid support. The first design element allows for a second round of specific hybridization to be imposed against closely matched competitors, while the second design element effectively excludes the nonspecific first capture probe-detector probe complex from subsequent rounds of capture. With the reduction in the background signal, the ultimate assay sensitivity is determined by the cumulative efficiencies of the hybridization capture and release steps. In the format described here, the conditions for hybridization capture and release have been optimized from physical measurements of the stabilities of the individual hybrid bonds.
The application of two independent and successive hybridizations with distinct ligand and antiligand capture pairs is a highly selective process in which nonspecific hybrids and nonspecifically bound probe complexes are effectively eliminated. With respect to nonspecific hybrids, close competitor target sequences are subjected to two successive hybridizations against the same probe sequences. The discrimination of a specific capture probe against closely related nontarget sequences is the product of the discrimination factor obtained for each hybridization event. This multiplicative factor translates to the detection of 103 C. trachomatis rRNA targets in the presence of a 108-fold excess of C. psittaci rRNA molecules.
In the case of nonspecifically bound probe complexes, the elimination of nonspecifically bound probe complexes results from both RTC and the use of two distinct ligand-antiligand pairs. RTC eliminates the vast majority of the nonspecifically bound reporter probe through the process of multiple and sequential cycles of specific capture of target complexes, washes, and target elution from the magnetic beads. However, under assay conditions of high capture and reporter probe concentrations, the high degree of sensitivity afforded by the Q-Beta amplification step allows detection of the formation of a very low level of nonspecific capture probe-detector probe complexes. A similar observation was reported by Van Ness and Chen (16) , who used oligonucleotide probes in chaotropic hybridization mixtures. Although the efficiency of this formation is extremely low (on the order of 1 in 108 detector probes), this type of noise subsequently cycles on and off the beads when a single ligand-antiligand pair is used (unpublished data). The presence of such complexes is below the sensitivity of standard isotopic methods. The application of two different capture ligand sets greatly reduces this carry through, because any capture probe-detector probe complex which is formed and captured via the first ligand-antiligand pair is unable to bind to the second set of beads containing a different antiligand. Pritchard and Stefano (11, 12) previously reported on the use of Q-Beta amplification and reversible target capture for the detection of human immunodeficiency virus type 1 pol region RNA. In those earlier studies, the technology was limited by the background signal, which corresponded to about 100 probe molecules which carry through the assay. Additional cycles of capture and release did not reduce this level of noise. It is precisely this type of background which is eliminated by the dual-capture format. However, an additional cycle of capture and release is still required to eliminate all detector probes bound nonspecifically to the solid support (9) .
In the dual-capture format, noise has been reduced by more than 11 A new amplified nucleic acid hybridization assay format, termed dual capture, has been developed. The assay uses two powerful and complementing technologies: Q-Beta amplification and dual capture-RTC. The assay can detect RNA or DNA targets by using the same assay chemistry. Competitor signal from C. psittaci was not detected by using RNA equivalent to 108 elementary bodies. The sensitivity of this amplified assay is 103 16S rRNA or rDNA molecules, which corresponds approximately to one chlamydial elementary body. The assay's high degree of sensitivity is afforded by the C29 detector molecule, which in the described format can be detected at the level of a single molecule.
In a limited study of 94 patient samples, the dual-capture assay detected 5 of 6 culture positive samples. When the signals from these five positive samples were compared with those from parallel rRNA controls, these samples contained C. trachomatis rRNAs which were consistent with levels of between 104 and 106 rRNA molecules per reaction mixture. As for the one false-negative sample, we attribute this difference to the sixfold difference in sample utilization between culture and the assay and not the inhibition of amplification. Our studies have shown that the signal is not affected by the presence of inhibitors in clinical matrices such as cervical mucus and blood (unpublished data). Additionally, PCR analysis of this sample was also negative (1) . The assay did not detect C. trachomatis target in 85 of 88 culture-negative samples. It is well known that some serovars of C. trachomatis are much less infective than others. Comparison of the response times in these three culture-negative samples with those of parallel rRNA controls indicated rRNA levels of between 104 and 105 molecules per reaction mixture. The presence of C. trachomatis nucleic acid in these three samples was confirmed by PCR analysis (1) .
The sensitivity of the assay described here should be sufficient for the detection of infectious organisms such as bacteria and fungi in clinical specimens. The dual-capture assay format is equally sensitive when the probe sets are modified to detect other organisms, such as Mycobacterium tuberculosis, and cytomegalovirus (unpublished data). For many of these pathogens, positive identification can take weeks and is often difficult and expensive. The successful development of the dual-capture assay technology is directed toward addressing these needs, and the dual-capture assay offers a rapid and sensitive alternative to traditional identification methodologies.
